Composite Lymphoma Containing Mantle Cell and Peripheral T-cell Lymphoma, Not Otherwise Specified: A Report of 2 Cases Treated With Up-front Autologous Stem Cell Transplantation

Marín, Isabel González-Gascón y; Menárguez, Javier; Kwon, Mi; Burdaspal, A.; Martínez-Laperche, Carolina; Castro, Yolanda; Infante, María Stefania; Díez-Martín, José Luís; Hernández‐Rivas, José‐Ángel

doi:10.1097/pai.0000000000000769

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Case 2 has remained disease-free for 4 years. Consolidation treatment with ASCT was performed after achieving first CR, which has achieved a long-term remission [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological analysis of composite lymphoma: A two-case report and literature review

Gui

Wang

et al. 2020

Open Medicine

View full text Add to dashboard Cite

ObjectiveThe objective of this study was to evaluate the clinicopathological features and treatment of composite lymphoma (CL) with cervical lymph node enlargement.MethodsIn this study, two cases of CL are presented. Biopsies of enlarged cervical lymph nodes by excision revealed two distinct types of lymphomas. The diagnoses were confirmed by routine histopathology, immunohistochemistry, in situ hybridization, polymerase chain reactions and flow cytometry. Case 1 was diagnosed with Hodgkin’s lymphoma and cytotoxic T-cell lymphoma complicated by Epstein–Barr virus infection. Case 2 was diagnosed with diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma.ResultsCase 1 received one cycle of adriamycin, bleomycin, vincristine and dacarbazine (ABVD regimen) combined with chidamide, followed by one cycle of gemcitabine and dexamethasone (GDP regimen) combined with chidamide, and then oral acyclovir. The patient achieved stable disease, but was lost to follow-up. Case 2 received eight cycles of cyclophosphamide, pirarubicin, vincristine and dexamethasone (CTOP regimen) combined with chidamide, and the patient achieved complete remission. Nine months later, relapse was confirmed. She received chidamide monotherapy for 3 months, which was then terminated. One year later, the patient underwent progressive disease and died.ConclusionsCL is a kind of rare disease. Due to the complexity of CL, clinicians should consider both disease components in order to increase the likelihood of effective treatment. This is important.

show abstract

“…Case 2 has remained disease-free for 4 years. Consolidation treatment with ASCT was performed after achieving first CR, which has achieved a long-term remission [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological analysis of composite lymphoma: A two-case report and literature review

Gui

Wang

et al. 2020

Open Medicine

View full text Add to dashboard Cite

show abstract

“…CL is rarely described in literature, and its description has been limited to isolated case reports (9)(10)(11)(12). However, its incidence may be underestimated as sophisticated techniques are required in the diagnosis of CL, and, due to its inconsistent definitions, the incidence of CL reported across different studies varies (13).…”

Section: Literature Reviewmentioning

confidence: 99%

Composite lymphoma of cervical lymph nodes with classical Hodgkin lymphoma and diffuse large B cell lymphoma: a case report and literature review

Wang

Zhang

2020

Ann Palliat Med

View full text Add to dashboard Cite

Composite lymphoma (CL) is a clinically rare entity, with unknown pathogenic mechanisms. Its diagnosis is quite difficult, and there is currently no proven treatment. In this article, we report a 64-year-old male patient presenting with swelling and mild pain in the bilateral cervical lymph nodes. Radiology revealed lesions only involved the neck. Histological examination showed that the tumor tissue had two components: mixed cellularity classical Hodgkin lymphoma (CHL-MC) and diffuse large B cell lymphoma (DLBCL).The final diagnosis was CL in the bilateral cervical lymph nodes composed of CHL-MC and DLBCL stage IA. The patient received six cycles of rituximab plus cyclophosphamide, pirubicin, vincristine, and prednisone (R-CHOP) and two cycles of rituximab maintenance therapy, and complete response (CR) was achieved. No progression was found during the 9 months of follow-up. We conducted a literature review of 28 cases of CL with CHL and DLBCL. The demography of the disease, the location of the disease involved, the subtype of CHL, the Epstein-Barr virus infection, treatment and survival were described in detail. In the discussion section, we analyzed the definition, pathogenesis, diagnosis, treatment and prognosis of CL. We hope that through case reports and literature review, we can improve the understanding of CL and optimize its treatment.

show abstract

Composite Lymphoma Containing Mantle Cell and Peripheral T-cell Lymphoma, Not Otherwise Specified: A Report of 2 Cases Treated With Up-front Autologous Stem Cell Transplantation

Cited by 2 publications

References 12 publications

Clinicopathological analysis of composite lymphoma: A two-case report and literature review

Clinicopathological analysis of composite lymphoma: A two-case report and literature review

Composite lymphoma of cervical lymph nodes with classical Hodgkin lymphoma and diffuse large B cell lymphoma: a case report and literature review

Contact Info

Product

Resources

About